Nufarm Limited (NUF) Earnings Call Transcript & Summary
November 13, 2024
Earnings Call Speaker Segments
Operator
operatorWe appreciate everyone joining us and are glad to have you on the Nufarm Limited FY ‘24 Results Call. Everyone attending is currently muted and will only be able to listen. After a presentation, we will hold a question-and-answer session. <<operator_script>> At this point, I’ll pass the conference to Mr. Greg Hunt, CEO. You may proceed.
Greg Hunt
executiveThanks, Harmony, and good morning, everyone. Welcome to Nufarm's Financial Year ‘24 results presentation. I'll just take a minute to draw your attention to the disclaimer on Slide 2 and in particular, the statement relating to forward-looking statements. Financial year 2024 was a tough one for the crop protection industry. Despite the challenges, Nufarm continued to make good progress with our innovation and growth strategies. EBITDA was at the midpoint of the revised guidance that we gave on the 15th of August. We had an outstanding result on networking capital with a 30% reduction on the prior year. This had a similar impact on reducing debt. We finished a year with net debt of $635 million, which was 25% below the prior year. Net leverage was 2x EBITDA, which is a very strong performance, given our reduced earnings. Applying our capital management principles, there will be no final dividend for financial year ‘24. As we move into 2025, we'll continue to tightly manage costs and our balance sheet. We have clear targets to reduce costs and working capital. We will increase our focus on improving our return on funds employed. However, we will keep investing in our growth platforms.
Greg Hunt
executiveOver the course of the year, we encountered competitive pricing as the industry pushed volume and cut back inventory, especially in North America. Demand stayed healthy, and our product sales exceeded the prior year's total. Channel inventories have come down, though reordering is still happening on a just-in-time basis. We keep capitalizing on robust performance from our crop protection pipeline. Products we've newly introduced accounted for over 15% of revenues. In Canada we brought Oxbow Herbicide to market. That country is the initial market in a lineup of herbicides built on Duplosan, our dichlorprop-p products. Oxbow is a serial herbicide that manages herbicide resistant kosher, a weed capable of causing 20% yield losses in wheat and costing Canadian growers up to a $100 an acre every season. Channel partners and growers welcomed the Oxbow launch very positively, and we intend to bring out additional Duplosan products in 2025. Switching to application technology: Nufarm teamed up with New Zealand Company Robotics Plus to design its Quantum sprayer technology for the Prospr robot. That complete solution is now distributed by us throughout Australia and New Zealand. We additionally made a modest investment in Norway-based Kilter, which is developing spray equipment employing advanced technology to target weeds precisely when applying herbicide.
Greg Hunt
executiveAlso, through a separate initiative, Nufarm has teamed up with a UK research firm called Moa to create herbicides that work through entirely new modes of action. We're bolstering our standing in sunflower, sorghum, and canola seed. Our hybrid canola share rose in Australia and Brazil, and we see genuine potential to build on our leading canola traits to fuel additional growth across South America. Omega-3 saw meaningful strides. We hit our goal of $50 million in omega-3 sales. We broadened the grower base and planted area as well, and our newest hybrid varieties delivered strong results. In July, we secured an exclusive license to Yield10's omega-3 camelina technology. On biofuels, we increased carinata plantings. Although biofuel mandates are still taking shape, our emphasis is on output from the most advantageous markets. We're striving to optimize our cost of goods and to establish market value. In 2024, carinata was added to Annex IX A of the European Union's Renewable Energy Directive, which makes carinata one of the few scalable agricultural technologies that satisfy the legislative criteria for SAF mandates. Now to segment performance in greater detail. In North America, underlying EBITDA came in 49% lower than the prior year. Price competition weighed on our margins.
Greg Hunt
executiveEven so, demand for Nufarm products remained robust. Revenue was level with the previous year, supported by solid volume gains. In Canada, Turf & Ornamentals posted results that matched the prior year. As I noted earlier, we also had a successful launch in Canada of the first of the products powered by Duplosan. In Europe, underlying EBITDA came in 25% lower than the prior year. Nufarm volumes and margins held up well in the European domestic market — foundational products faced pricing pressure. That said, we performed strongly in the higher-margin TNVV, meaning trees, nuts, vines and vegetables crops. Roughly 65% of what we produce at our Wyke facility goes to Nufarm and third-party customers outside Europe. Sales volumes declined, driven by weaker demand, especially in the China green roofs market and in North America, both to Nufarm and to third-party customers. We are taking action to cut cost and improve returns in our European segment. Our APAC segment reported EBITDA of $88 million, in line with the prior year. Demand for Nufarm products was strong. Australia was hurt by low 2,4-D prices. In New Zealand, weak farmer economics weighed on sales and volumes. Asia delivered an exceptional result, with EBITDA growing on the prior year.
Greg Hunt
executiveAsia is among the regions delivering the strongest growth and the highest return on funds employed. At Laverton, we increased 2,4-D capacity by 2,4-D capacity expansion. That lowered what it costs us to produce and reinforced our ability to supply customers worldwide. It leaves us well placed to react when duties on 2,4-D are introduced in the United States. In seed technologies, EBITDA came in 15% under the prior year, mainly because licensing revenue was lower than a year earlier, and because costs are higher as we scale our omega-3 and biofuels platforms. Canola performed strongly in Australia, where our new TriFlex hybrids delivered greater revenue and margin. We grew our position in South America, drawing on southern hemisphere adapted genetics from Australia. We acquired Labuan, a distribution business in <<inaudible>>, to give more support to our canola and Carinata expansion. We also licensed our sunflower hybrids out in the Europe and Eastern European markets. It was a significant year for omega-3. We hit our target of $50 million in revenue. We grew both our grower base and the planted area. Our 2024 crops showed further improvement in grain yields, along with a better oil profile. We entered the license for a yield tens, omega-3 camelina, and that transaction gives us a chance to broaden our omega-3 portfolio with additional oil profiles and the potential to produce omega-3 in winter camelina crop that is grown as a cover crop while still in the development phase.
Greg Hunt
executiveWe anticipate a strong synergy between this technology and pipeline and our current omega-3 canola platform. Unseasonably wet weather plus the late soybean harvest held back our Carinata expansion plans in Argentina, and we couldn't get all the contracted hectares planted. We grew in <<inaudible>> and launched in Brazil, where the harvest was very successful and there's momentum behind planting more in 2025. Grower demand in Argentina stayed strong. We moved our breeding pipeline forward with better deals, improved oil content, shorter maturities, and testing of herbicide tolerant traits. Even though we expect industry conditions to get better, we aren't sitting aware waiting for that to happen. We have clear priorities for improving business performance regardless of where the cycle moves. By the end of financial year ‘25, we're targeting $50 million in analyzed annualized savings in overhead costs. These cost reductions focus on non-revenue generating functions. We want to run things in a leaner, more efficient way. We're also targeting a 25-day year-on-year reduction in inventory, again by the end of financial year ‘25. We're refining our planning processes and behaviors so we can operate with lower stock levels that still meet customer demand.
Greg Hunt
executiveAll of these efforts, along with others, are intended to boost how efficiently we generate profit and use capital. We must achieve a stronger return on the funds we employ. Our growth priorities are well defined. We intend to keep expanding omega-3 and biofuels. We'll invest in areas where we think we can succeed — including reinforcing our Phenoxy platform through the investment at Wyke, concentrating our portfolio spending on areas offering more immediate impact, and drawing on our leading positions to achieve further growth in canola, sorghum, and sunflower seeds. I'll now pass things to Paul, who will walk you through the financials.
Paul Townsend
executiveThanks, Greg, and good morning, everyone. Sales came in 4% lower than the previous year, underlying EBITDA fell 29% versus the prior year, and underlying EBIT dropped 57% compared with last year. Statutory net profit showed a loss of $6 billion. Material items took in idle plant costs tied to improvements made at Laverton and Wyke, along with restructuring costs. Those costs were partly offset by a gain on the sale of surplus land and the utilization of a deferred tax asset. We posted underlying basic earnings per share of negative $0.063. As financial year 2024 closed, net debt stood at $635 million, 25% lower than the year before. Net leverage came to 2x underlying EBITDA. The drop in net debt was chiefly driven by a decrease in net working capital, which I'll cover in more detail on the next page. Return on funds employed was 4%, 490 basis points under the prior year. The decline in return on funds deployed stemmed mainly from lower underlying EBIT relative to last year. Revenue was down 4% across the year. That decrease was largely attributable to weaker selling prices and an unfavorable mix shift in crop protection. Average selling price eased slightly in the second half.
Paul Townsend
executiveVolume growth came in strong for us, and that helped partly counter the drag from price and mix. In seeds, revenue rose thanks to how well our canola hybrids performed. Bioenergy revenue came in lower because we had less licensing revenue, and as Greg mentioned, omega-3 revenue grew. Net working capital came down 30% versus the prior year. That decrease came from lower inventory, payables returning to normal, and solid execution on managing receivables. Net working capital sat $710 million below the first half, which reflects the seasonal swing in working capital plus the inventory reduction. We've said many times that this is a seasonal business, and fluctuations in working capital between halves are simply a normal feature of how we operate. This half's unwind is in line with — in fact, pleasingly better than — what we reported at the half one results in May. Operating cash flow reached $472 million for financial year ‘24. The strong cash conversion reflected that net working capital reduction. Cash conversion has averaged 73% across the prior 4 years, and I'd note we stay focused on that objective. On working capital, we ended the period with inventory down $300 million, or 20% year on year.
Paul Townsend
executiveBy making progress in things like advanced <<inaudible>> forecasting, supply planning, seasonal business planning, and supply chain agility, we anticipate being able to cut inventory further and do so sustainably, without any negative effect on customer service. We keep seeing payables return to normal as the business shifts toward a more typical replenishment cadence. Trade and other receivables matched the prior year and showed discipline on commercial terms in a competitive environment plus strong collections performance. On capital expenditure, it came to $230 million for the period. That included targeted investments for HSE and plant reliability at Wyke and for growth to Chicago Heights and Laverton in the 2,4-D area. These investments are meant to cut plant downtime and strategically expand capacity, and they have a strong near term payoff. We continue investment to grow our seeds platforms, which remains a high priority. We also put money into a number of small strategic investments of around $50 million, which Greg covered earlier. In FY ‘25, we expect capital expenditure to be around $230 million. Seeds and portfolio CapEx are expected to be in line with the prior year. Most of our seeds CapEx keeps going into our omega-3 and Carinata growth platforms. Supply chain CapEx excluding Transcend is expected to be lower than the prior year.
Paul Townsend
executiveWe keep evaluating the investment in Transcend, a plan to expand Phenoxy manufacturing capacity at Wyke and preserve our position as global leader in Phenoxy herbicides. Transcend awaits a final investment decision, and we expect to make that call in the first half of ‘25. Regarding net debt as used in this presentation, we've given you a somewhat different view of our net debt, which we hope helps you better understand how we manage our deposition. On the left side of the graph, you can see our asset-based lending facility. The ABL is secured against receivables and inventory, and it flexes up and down with movements in those balances. Because our networking capital position was lower, ABL utilization was lower at the end of financial year ‘25 and financial year ‘23. We show remaining net — we show remaining debt net of cash balances as core net debt. This largely consists of our U.S. senior unsecured notes standby liquidity facility and local bank facilities. Neither the U.S. notes nor the syndicated loan facility carries financial maintenance covenants. Our targeted net leverage range of 1.5x to 2x EBITDA reflects our wish to keep leverage conservative through the cycle.
Paul Townsend
executiveDepending on where we are in the cycle, it's possible for that figure to fall short of the bottom of the range or to exceed the top of it. For the most part, those swings mirror cyclical movements in networking capital and earnings. Once more, I want to stress that this leverage target has nothing to do with whether debt covenants exist; our capital management principles are what set it. When financial year ‘24 closed, total net debt stood at $635 million, which is a 25% reduction on the prior year. That decrease in net debt came mainly from a driven reduction in networking capital. We had $355 million of undrawn facilities at balanced day net leverage was at 2x EBITDA, which sits at the upper end of our target range. We take a great deal of pride in that outcome given cyclically lower earnings. And finally, just to help you with your modeling for financial year ‘25, we expect depreciation amortization expense of around $210 million. Net interest expense including the cost of FX hedging expected to be around $90 million and we expect an underlying effective tax rate of 26%. Capital expenditure is expected to be around $230 million. Now, I'll hand back to Greg.
Greg Hunt
executiveThanks, Paul. Now, on the outlook. Look, providing earnings guidance at this point would be premature, since there's genuinely a long way to playout. So instead, I think I'll try to give you some color on how we're seeing our markets. End use demand is solid, and for our crop protection products we are starting to see stable active ingredient prices. So we're not expecting the same deflationary drag from falling AI prices that we saw in financial year 2024. As a result, the outlook seems far more positive for our crop protection business. The setup for canola, sorghum, and sunflower seeds is also positive, but as always subject to the weather. We are targeting growth driven by supportive crop prices and multiple long-term demand drivers in food, feed, and energy. We continue to invest to grow our omega-3 and our biofuels platforms. There has been some downward pressure in fish oils and biofuels pricing recently that will make it challenging to improve the profitability of those platforms in financial year 2025. The outlook for plant-based omega-3 products is strong over the longer term. There is a constrained supply of fish oil and global, and growing global demand for omega-3.
Greg Hunt
executiveRight now, we feel good about what we've said regarding roughly a doubling of revenue in financial year ’25. That does still depend on pricing as well as broader market conditions. In our view, expansion in mandates gives biofuels solid long-term fundamentals. We're mindful about pricing supply, so we don't run too far ahead of demand. This business is at an early stage, so patience will be needed while we scale. GHG premiums in the U.S. have stayed low, and the policy landscape is clearly somewhat in flux. Because of that, we've chosen to scale back plantings in the U.S. Brazil and Argentina look favorable to us for carinata cultivation. Now to the financial outlook. Management's focus is on cutting costs and working capital, lifting return on funds employed, and backing our growth platforms. Net working capital when the first half of ’25 closes should be consistent with the first half of ’24, with more investment needed to support omega-3 growth. Our target is $50 million in annualized overhead savings and a 25-day reduction in inventory year on year by the close of financial year 2025. We keep working toward our financial year 2026 revenue aspirations of $600 million to $700 million from seed technologies and $3.8 billion to $3.9 billion from crop protection, which clearly hinges on pricing returning to its long-term average.
Greg Hunt
executiveWhen you look at the revenue side of crop protection, we're performing well through new product launches and by capturing market volume. Our numbers make that clear. What we can't control is market pricing. We do anticipate that pricing will improve from where it stands now, though how far that goes across the coming two years is something we can't forecast. With a larger omega-3 canola harvest in 2024, we're expecting omega-3 revenues to double in ‘25, provided current market positioning holes hold. During financial year ‘25, our priority is better returns. I've discussed this with Brent Zacharias and Rico Christensen — Brent oversees growth for our seed technologies and platforms, while Rico handles our crop protection platforms. Both of them will now join Paul and me for the Q&A session, and I'll turn things back to Harmony to get that started.
Operator
operatorThe opening question is from Evan Karatzas of UBS.
Evan Karatzas
analystMorning, Greg and Paul. To start off with me, could you describe your view of the crop protection sector, particularly when it comes to pricing and the possibility of surplus output or capacity emerging from China? And then, I suppose in connection with that, how that factors into whatever expectation you hold for those GP margins recovering from the sort of end FY ‘24 levels we see at present, please.
Greg Hunt
executiveYes, thank you Evan. I think that is quite a significant question, so I will attempt to address it from several angles. Let us begin with the structural issue, and really it is too — has additional manufacturing capacity been built in China? Clearly, the response is affirmative. So if you had a substantial manufacturing presence outside China, that could pose a problem for you. And let me simply note that across the past five or six years, we have cut our footprint considerably, and today we operate two highly focused facilities, synthesis facilities. One of those, naturally, is located here at Laverton, where 2,4-D is produced. I feel confident about that plant's competitive position, especially given that we have the 30% tariffs on 2,4-D imports. And provided the Australian government wishes to preserve what we regard as sovereign capability, it ought to stay competitive. The other facility, naturally, is the operation we run at Wyke, which mainly makes MCPA, and in that molecule we lead globally. So essentially, we are discussing two active ingredients, and for virtually everything else we purchase from manufacturers based in China and India, and the real question for that everything else is whether we have competitive sourcing arrangements in place?
Greg Hunt
executiveYes, that's correct. So I hope that addresses the structural side of things. Now, regarding how the cyclical side unfolded for us amid the recent downturn — there are probably three points worth making. The first is that we had to work through the higher-cost inventory, and as we restocked, prices kept falling, and that drag persisted across ‘24. I think we gave you some reference points when we updated you back in August. What we're telling you now is that over recent trading, prices have stabilized. That stabilization matters a great deal in why we're indicating the outlook for ‘25 appears improved relative to ‘24. The second point is that while distributors were cutting inventory, their need to reorder was naturally weaker than usual. And there was still stock held by Nufarm and, clearly, by our competitors. That circumstance produced more intense price competition than we'd typically see. And as you can tell from our inventory result — and many across the industry — those legacy inventory balances have by now mostly been worked off.
Greg Hunt
executiveA few pockets remain, but on the whole I'd describe the supply inventory as normal. Distributor inventories, on the other hand, sit at low levels. I'd almost go as far as saying that in the event of a supply bottleneck or a supply shock, things could flip quite fast and the channel would be scrambling for inventory. And then the third and final point, I suppose, is that cyclical upward pressure on prices will be there. What's the basis for that? Well, one reason is that manufacturers based in China — particularly those in China — are now earning single-digit returns. So the price cuts ex China had come at the cost of profitability. And I don't know when — I can't predict when or how that situation plays out. We said we can't predict what will happen with pricing. But it does look to us that the current low level of industry profitability means that there's more chance of upward pressure on prices than downward pressure on prices and the downward pressure on prices that we've seen over the last 18 months. Hopefully that sort of tries to cover or give you an answer on the structural and the cyclical issues.
Evan Karatzas
analystYes. No, it does. So yes, that's really useful color and detail. Okay. So just one last follow-up on that. If pricing stays where it is now, you ought to see a natural GP margin recovery, since you wouldn't have what you're describing — a bit of pressure on your COGS, sorry, your end market price and the COGS. So is that the right way to think about it?
Greg Hunt
executiveYes, that's right. And in recent trading, we've noticed better margins on, I'd say, comparable volumes in North America, and as you mentioned, COGS have now caught up with the lower prices coming out of China. In Europe, we're definitely seeing a modest margin gain, with sales and volumes stronger once more. High COGS inventory is mostly being sold through. I mentioned a couple of pockets, and one of them is in Europe, where we typically carry higher volumes of insecticides and fungicides. But I don't view that as a material issue. And here in APAC, margin matches what we saw last year, again in early trading. But volumes are higher, and we're definitely seeing an improvement in 2,4-D pricing, which is certainly a tailwind compared with where we stood at this time last year.
Operator
operatorWe go next to William Park at Citi, who has a question for you.
William Park
analystThanks, Greg and Paul, for fielding my question. I’d like to ask about payables as we head into, I suppose, the first half of FY ’25. I appreciate that you’ve managed to lock in and improve customer terms, negotiated those terms with suppliers, and that stock management has become more effective. So may I ask how you’re thinking about payables? Does it return to roughly the first half FY ’24 level? So should we expect it to be somewhat more elevated? I just wanted to get your sense of how you’re thinking about payables.
Paul Townsend
executiveYeah, thanks, I suppose. I think the lens to use here is payable days, and we believe we're roughly at the level we anticipated. As far as the average payable goes. So what really matters is the ratio between inventory and payables. During the second half we brought that down by roughly $60 million, and we anticipate further gains as we continue cutting inventory. So payables alone shouldn't be your focus. What you actually need to examine is how inventory and payables relate to each other, and we believe there's room to squeeze that further. And that builds on the 25-day reduction Greg brought up. Now that 25-day cut — since I know that came up in your questions during the first half — is in fact aimed at year-end. So across the first half we don't anticipate much change, though there'll be a small amount, but the genuine effect arrives near the close of FY ‘25, when we can achieve that more durable inventory reduction and thereby compress the payables-to-inventory relationship even further.
William Park
analystAnd maybe, if we could shift focus to licensing revenue, could you help us understand roughly how large that figure was during the second half, and what we ought to anticipate moving forward?
Paul Townsend
executiveMy apologies — could you say that again? Which revenue figure are you asking about?
William Park
analystAnd turning to licensing—what about the revenue from royalty licensing?
Paul Townsend
executiveYeah, that figure appears in the notes we provided — the prior year came in at $55 million. This year, I believe it's roughly $46 million. So you're looking at a shift of around $8 million to $9 million.
William Park
analystAnd what about expectations from here on out—sorry?
Paul Townsend
executiveYes, we do anticipate that this revenue will decline, since a significant portion of it—as we discussed last year—was tied to the BP arrangements. So we anticipate that revenue coming off further next year. So you should expect it to be down.
William Park
analystThank you. And my final question concerns the possible effects of U.S. tariffs. So if you consider the crop protection business in North America, especially in the U.S., I know you mentioned that purchasing decisions are still being delayed broadly, but with the potential for this U.S. tariff being introduced, are you seeing any early indications of purchasing decisions being brought forward?
Paul Townsend
executiveI’ll address that from a couple of angles. First, duties were announced not long ago—within the past few weeks—on 2,4-D, and they apply to manufacturers in China and India. For Chinese producers, the rate reaches 127% at the top and is 17% at the bottom, depending on the manufacturer, while tariffs from India are around 8.5%. That’s a favorable setup for our manufacturing operations in Australia. And as I mentioned, we increased that operation—or that production capacity—during 2024. On tariffs more broadly, speculating is simply premature. We don’t yet know the what, the how, the when, or the where. That said, overall I’d describe us as fairly comfortable with where we stand. As I noted, we export from Wyke. Our Wyke operations in the UK serve our businesses around the world and some third-party customers. Nothing suggests tariffs will apply to the Wyke. As I said earlier, we have some flexibility to source from the regions that are most advantaged. So I definitely don’t expect us to be worse off than competitors. And in certain cases—such as 2,4-D made here in Australia for the U.S. market—we could end up better off.
Operator
operatorThe following question is from Reinhardt van der Walt of Bank of America.
Reinhardt van der Walt
analystMorning, Greg and Paul, and thanks for taking my question. Greg, I wanted to follow up on what you said about the structural dynamics in China. You noted that returns for Chinese manufacturers are in the single digits right now. But if you look at some other materials sectors, the Chinese could potentially sustain those low returns for quite a while. How do you see the cycle playing out? And how do you think the market will digest the risk that Chinese production doesn't actually become disciplined on pricing? What I'm trying to understand is whether that pricing discipline from China is a must-have prerequisite for a material recovery here.
Greg Hunt
executiveHonestly, the only way I can truly respond to that is—well, suppliers do exist. I don't think I can expand much beyond the remarks I gave before. The sole effect we've experienced involves our center's operations here, in the UK, and in every other case, we're able to purchase from China and from India. And volumes from India are beginning to rise now. Sure, we remain heavily dependent on China—I acknowledge that. Even so, we also have the choice of sourcing certain active ingredients from India.
Reinhardt van der Walt
analystNoted, and thanks for the added detail. One quick follow-up: you said a handful of areas in your portfolio still show surplus manufacturing inventories. Could you tell us which particular product categories those are?
Greg Hunt
executiveWell, I believe what I said had to do with a few small pockets, particularly in Europe, where because of how the ‘24 season played out, some insecticide and fungicide applications were missed, and we're carrying part of that inventory into 2025. Other than that, which I'd call fairly immaterial, we've worked through all of the inventory that was priced higher and are well positioned as we head into ‘25.
Reinhardt van der Walt
analystRight, got it—understood. So would it be fair to assume, now that the high-cost inventory has worked its way out of the system, that margin recovery might look quite V-shaped or L-shaped? Or do you expect margins to recover in a somewhat more symmetrical fashion across the next 2 years?
Greg Hunt
executiveWell, I suppose that's the question worth $90 million. What I believe we're indicating is that the drag we experienced in financial year ‘24 from declining active ingredient prices won't recur. Assuming AI prices have stabilized, we ought to see that improvement materialize in financial year ‘25.
Reinhardt van der Walt
analystAnd maybe just one final question, just about some of those cost reductions you're pointing to. Is this kind of a case of not letting a crisis go to waste and finding opportunities for some permanent cost out? Or is it just variablization of some of your cost base, and can we expect some of those to eventually come back in again?
Paul Townsend
executiveThese represent genuine cost reductions, and in fact several of these initiatives are already in place — that's precisely why we have a restructuring provision in the accounts, which we flag, along with the material items. I'd also like to note that we don't expect these savings to come at the expense of any of our growth projects or other growth initiatives we have underway. So we really need to ring-fence those costs — essentially overhead, back-office type support costs — and those are what we're targeting. So none of our growth agendas will be affected. Another point is that we will be reporting on these, and the other side of it is that the question becomes how do we view them. What we need to do is separate out what counts as our growth investment and what will be our volume growth, because within our SG&A expenses you also have distribution costs sitting inside those figures. And then we'll have to sort of demonstrate how we actually — what savings we've delivered through those overhead reductions. So we're very clear on this in terms of how we're going to pursue it, and we're clear on how we're going to report on it, because the issue is that it won't be absolutely visible in our accounts.
Paul Townsend
executiveThat means we'll need to offer a genuinely solid bridge so that everyone — including us, the board, and the market — can see how we're tracking against these cost reduction initiatives.
Greg Hunt
executivePerhaps, to add one more thing on that, we expect our volume in crop protection and seeds to grow in 2025. And insofar as we achieve that, those costs tied to volume are going to rise. I think, as Paul said, the key result is that these savings assist us in becoming more efficient and more competitive, help us increase our profit and prove our returns. And as Paul committed, we will update you on the progress and the savings that we are generating as we move through ‘25.
Operator
operatorOwen Birrell of RBC has the next question.
Owen Birrell
analystI just want to add a quick follow-up to what Reinhardt asked about the cost savings. You mentioned $50 million in annualized cost savings. Could you help us understand whether that figure represents an end-of-period run rate, or whether you expect to reach that $50 million over the course of FY ‘25?
Paul Townsend
executiveCorrect, that figure represents the run rate as of the period's close. There will, of course, be a partial effect during this year, yet the complete effect arrives in FY ’26 — so what we’re citing is the run rate at the end of the period.
Owen Birrell
analystCould you help us understand, I suppose, where those targets originate, so we can get a sense of, I suppose, how attainable they really are? What I mean is, if it's simply a matter of reducing headcount, then obviously that's far more attainable than if it involves generating productivity gains or cost efficiencies.
Paul Townsend
executiveYes, so I’d say over 50% will come from reducing headcount. But as we’ve said, the key thing is that we have to redesign processes. You simply cannot cut staff and then expect the same work to be done the same way by the same people. So this involves redefining how our processes work. How do we redefine? What we do and what we don’t do? So there’s a great deal of work underway there. So — coming back to your question, most of it is headcount, so that will be much easier to achieve. That said, however, we need to put revised processes in place so that we can be effective and efficient going forward.
Owen Birrell
analystAll right, and I suppose I have a second question. Looking at the omega-3’s platform, you've kind of restated the goals of roughly doubling those revenues in FY '25, and I believe your wider seeds revenue targets of, what, $600 million to $700 million by '26. I just wanted to get a sense of how much the softer near-term pricing is affecting that. Are you sort of, I guess, having to raise volumes to sort of reach those targets, hence the higher investment? Or had you already sort of accounted for this level of volume target?
Greg Hunt
executiveLook, I think maybe I’ll have Brent join us in a minute. But I think it’s kind of important that we understand where we are on our seeds journey. And as I said in the remarks earlier, the first point is that we’re confident in the long-term growth of our base seeds business, as we call it—our sunflower, sorghum, and canola. I mean, that is a material contributor to the $600 million to $700 million revenue aspirations. Growing our omega-3 and biofuels to a level where they make a meaningful contribution to profit will take longer—more time. And as we’ve shared with you today, the variation in market pricing does have an influence on the rate of revenue growth. And maybe, Brent, if you could come in and maybe make some specific comments around fish oil prices and just how we see that playing out over the next year or two?
Brent Zacharias
executiveAbsolutely, and thanks for raising that, Owen. So I think if you take one of the benchmarks we consider most relevant for tracking North Atlantic fish oil pricing, in September it was roughly $3,200 per metric ton, and as recently as May 2024, that price stood at $5,000 a ton. So pricing has come down faster than we expected, and I think faster than the entire industry expected. Even though the market is more competitive, the answer to your question is yes, obviously we'll need to sell more volume to hit that kind of revenue under the pricing currently in the marketplace, but it does move quite quickly. The market is competitive, but our focus is on establishing Omega 3 as a reliable alternative source of feed in the agriculture industry. And recently, we've also commented on expanding our position in human use. So I'd say we're comfortable with the progress that we're making on scaling the platform. And as Greg had mentioned, the new varieties that we're growing are improving the productivity of that crop and our oil profile. I'd just maybe conclude by saying we do have a scalable platform with constantly improving cost positions that doesn't require us to invest large components of capital investment like other technologies do.
Brent Zacharias
executiveWe feel pretty enthusiastic about our current position and the strides we've taken, including over the past year, when it comes to revenues.
Owen Birrell
analystYou mentioned — someone brought up earlier that earnings from the seed platform were somewhat depressed due to some extra expense involved in expanding that platform. Can you put a number on that extra expense and help us understand whether it's a one-time cost or an ongoing one that we should be building into our models?
Greg Hunt
executiveYeah, I think Paul mentioned that one factor behind the impact was likely mainly a drop in licensing revenue, but the higher cost we incur to scale both the omega-3 platform and our biofuels platforms also plays a part, to a smaller degree, and I'd say that cost will become variable and scale as volumes step up over time, though it isn't all that significant. It's really about leveraging the sales teams and the people on the ground that we have in our key markets — the U.S. supplying most of our omega-3 platform and Latin America supplying most of our care and auto platform.
Owen Birrell
analystCould you go over those North Atlantic prices again, just so I'm clear on them?
Greg Hunt
executiveRight. So September saw the North Atlantic market at roughly $3,200 per metric ton, while in May it reached as much as $5,000 a ton.
Operator
operatorSteve Byrne of Bank of America has the next question.
Steve Byrne
analystI was really, really interested in hearing what you expect for 2,4-D demand in the US. You brought up the duties recently placed on Chinese imports of 2,4-D, but I'm just wondering whether you're also seeing demand for 2,4-D rise in the states, given that Dicamba isn't available right now. And it's a leading alternative for broadleaf control. So is that pushing demand your way as well? And maybe a longer-term question: do you see an opportunity for your 2,4-D to be applied — as a post immersion application on cotton and soybean crops that tolerate 2,4-D, the Enlist trait?
Greg Hunt
executiveTaking your second question first, Steve, and thanks for asking. As you know, we lack a license that would let us apply over the top of those crops. That's why our attention has really stayed on burn down and post-harvest applications rather than over the top. We have definitely observed — and over recent weeks, with speculation swirling about what the tariff levels might be, we have observed stronger demand for 2,4-D, and now that the tariffs have been announced, we're working through how and from where we'll supply that market, and we have very solid supply relationships out of China for 2,4-D into the North American market. As I think you're aware, certain suppliers faced differential tariffs. Our main supplier is probably advantaged relative to some others, so we view that as a positive for Nufarm, and given the increased production here at Laverton, and where we see demand in the domestic market, it gives us the ability to channel — and we haven't really made a decision yet on what volumes we'll channel from our Australian production into the North American market. But I think the point I was making is that at least we have that flexibility.
Greg Hunt
executiveYour observation about Dicamba is spot on. We believe 2,4-D stands to gain from those shifts in regulation.
Steve Byrne
analystAlso, could you get on a path toward over-the-top 2,4-D spraying—you brought up a possible license. Might that route open up for you? And I’d like to ask as well about gene editing within your seed platform. There is clearly a great deal of expansion happening out there through gene editing being used for traits that aren’t GMO. Does that present an opportunity for you? Are you already applying this technology to boost yields or oil content? Or might that be an opportunity further out?
Greg Hunt
executiveMy view is that this represents more of a chance further out. Definitely so for carinata, and possibly camelina too, along with the other specialty crops we're concentrating on. We're putting some effort into traits work, though that will require a while. For sure, it won't make a material difference to earnings over the short term.
Steve Byrne
analystSo Greg, what about that upside opportunity for you—could it actually happen?
Greg Hunt
executiveYes. Look, as I believe you're aware, those licenses are held by one of the big companies in this space. We'll keep talking with them. But honestly, to be clear, in the near term I don't have much confidence that we'll secure an over-the-top license.
Operator
operatorScott Ryall of Rimor Equity Research has the next question.
Scott Ryall
analystHello there, and thanks a lot. I’ll start with a couple of quick questions, then move to one that’s a bit longer. First, could you verify whether your goal for inventory days is a reduction of 25 days across this year, and what figure do you regard as your inventory days for this year? I haven’t been able to locate it among the materials you disclose. I’m aware of what my own calculation indicates, but I’d be curious to hear yours.
Paul Townsend
executiveYes. Okay. Let me pull up my notes here. Give me just a moment. The figure we have in the calculation is 143 days. So you bring that down from 143 to 25 days. Now keep in mind, when you look at that, the calculation gives you roughly $150 million in net inventory reduction. But you also see a decrease in payables, because you don't — it just doesn't flow straight to the bottom line. There will be a reduction in payables as well, but it's really about factoring in that you narrow — you narrow that inventory-to-payables relationship even further. That's the point. So net working capital is one, and top up. I haven't seen that, but certainly that's squeezing.
Scott Ryall
analystYes. Got it. Thanks. And regarding the first-half results — in Appendix 11, you previously provided price indices for the major product groups, but this time you haven't included them. I'm just curious, given what you've said in your commentary, would it be fair to conclude that for herbicides, fungicides, and insecticides — the price indices you used to report — there hasn't been much movement since the first-half result?
Paul Townsend
executiveRico, would you like to say something about pricing?
Rico Christensen
executiveSo let me just — my understanding of the question was this: have you noticed any meaningful shifts when it comes to pricing in the second half, or…
Scott Ryall
analystRight, so that period really does run past the second half. You presented three charts covering herbicides, fungicides, and insecticides against the longer-term average, and I'm simply trying to gauge whether much has shifted there across the past six months since those charts were shown.
Rico Christensen
executiveSince we provided those charts, there haven't been any significant shifts at this point, and that's also—sorry—what Greg brought up before: pricing has mostly stayed stable over this stretch.
Scott Ryall
analystI just wanted to clear something up about the mean, thanks. Then, in what you presented today, in Appendix 10, you listed the entire global crop protection product development pipeline, and given that a couple of these products have actually landed and formed part of the sales mix across the last 12 months, could you comment on how meaningful they are within the roughly $2.9 billion in sales that you reported for fiscal ‘24, please?
Greg Hunt
executiveI think, on that point, Rico, perhaps you could walk through how we approach new product introductions in our prepared remarks. We mentioned that 15% of revenues in ’24 came from new product introductions. Could you maybe shed some light on how we, well, how we track that, how we measure it, and what impacts we expect in ’25 and ’26 from NPIs.
Rico Christensen
executiveYes. And as we noted in the release too, at present we're at what we refer to as an innovation rate of 15% of NPI — which means that 15% of crop protection revenue comes from new products that have been relaunched recently. That figure will move a bit, though not much, across the years ahead. So each year we generally sit around that 15% innovation rate. And we expect to see the same in ’25 and ’26.
Scott Ryall
analystSo if something shows up there as being within one year, then you wouldn't count it as part of the NPIs for the next year, since it's more entrenched by then? Is that the idea?
Rico Christensen
executiveWe usually follow something we refer to as an NPI for a period of five years. So even five years after launch, it's still counted as an NPI. The reason behind that is launches tend to be staggered — we don't bring a product out across every market simultaneously — but in the markets where it has launched, for example Australia in ‘23, tracking will continue through the end of ‘27. And then, if it launches in, say, the U.S. in ‘24, tracking will run through the end of ‘28, and it's treated as an NPI across that five-year span.
Scott Ryall
analystMy final question is this: over the past while, there has been considerable change regarding what the European market will accept when it comes to chemicals across parts of your portfolio, fertilizers included and beyond. Is there a metric you could give us to help us understand, for your sales into every market outside Europe, what share of your products could not be sold into Europe?
Rico Christensen
executiveThat figure isn't something I have on hand right now, no. There are certain products we sell in markets beyond Europe that have been discontinued within Europe, though the amount is not material. And actually, what we've observed is that usually in Europe, when we anticipate a product being discontinued, there are the usual delays — which in practice means we keep that business not just in the EU but in other markets worldwide as well. Still, it's not a meaningful number.
Scott Ryall
analystAll right, thanks. That is the —
Paul Townsend
executiveLet me add a few thoughts on that. In my view, the regulatory picture in Europe differs entirely from the one in the Americas and in APAC. Back in 2022, when we discussed our revenue goals for crop protection, we did highlight $170 million of cannibalization along with $130 million in revenue impact from regulatory outs in Europe. That is now behind us, and for 2025 or 2026 we anticipate no material regulatory outs in Europe.
Scott Ryall
analystGreat, that’s really useful. Thanks. That was everything I had.
Greg Hunt
executiveScott, I just want to make sure it's clear that the 143 figure represented an average of our inventory days, while the ‘25 number is based on our ending inventory days, which came to 170 — you should be able to work out the calculation from that. So the closing inventory days were 170, and the 143 was our average. I just want that to be clear. The ‘25 is based on 170.
Operator
operatorThe following question is from John Purtell of Macquarie.
John Purtell
analystMorning, Greg and Paul. Trust you're both doing well. Only a few quick questions. I realize you haven't provided guidance for the coming year. Still, when it comes to first-half versus second-half SKUs, maybe just some broad directional comments would help. Over the last few years, I believe we've tended to see a strongly skewed pattern — roughly 70%-30% in style for EBITDA between the first and second halves. Directionally, do you expect that to become somewhat more normal? In the past, I think you've mentioned something like 55%-45% as being closer to normal.
Greg Hunt
executiveYeah. So somewhere in the 55%-45% to 60%-40% band, John, that's pretty typical. You could probably even meet in the middle if needed, though it really hinges on where we end up selling and so on. But we're roughly thinking within that 55%, 60% to 40% to 45% range.
John Purtell
analystThanks. And Paul, typically we obviously see a seasonal pickup in that working capital and in that first half and the gearing as well. Just trying to sort of get a sense of what that's looking like for the first half from what you can see, I suppose just in terms of the working capital uplift. I know you've given some commentary on that, just trying to think through that.
Greg Hunt
executiveYes, and we kind of said we anticipated net working capital would look much like it did in the first half of last year. That means by the close of the first half of this year, at ’25, it should be comparable to where it stood at the end of the first half of ’24. The reason behind that is volume growth, so crop protection will simply expand in the usual seasonal pattern, consistent with what we've done before. But the key point is the scaling of our mega three business especially. That will call for, or need, a considerable amount of working capital investment. So that represents a sizable portion, roughly 100 million of the — if you think of it as one component of the first half position.
Operator
operatorThat brings us to the end of the question-and-answer session. I'll now return the floor to Mr. Hunt, who has some closing remarks.
Greg Hunt
executiveThanks, Harmony. And thanks to all of you for spending time with us today and for your interest in Nufarm. We're looking forward to connecting with some of you in the next few days. Thank you.
Operator
operatorThis brings today's conference to a close. We appreciate everyone joining in. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nufarm Limited transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nufarm Limited earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nufarm Limited or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.